FDA approval for Onsolis anticipated during summer 2009

FDA approval for Onsolis anticipated during summer 2009

Since August 2008, Meda and BioDelivery Sciences International (BDSI) have
worked in close collaboration with the U.S. Food and Drug Administration (FDA)
to complete the final requirement of a Risk Evaluation and Mitigation Strategy
(REMS) program for Onsolis (fentanyl - treatment of breakthrough cancer pain).

Last Friday, FDA's review Division informed Meda and BDSI that they had reached
agreement with the REMS for Onsolis, but that the FDA needed some additional
time to complete the final senior level sign off. Meda therefore expects Onsolis
to be approved by the FDA during summer, which could enable a fourth quarter
2009 launch, as previously anticipated.

For more information contact:

Anders Larnholt, VP Corporate Development & Investor Relations	tel. +46 709 458
878

MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships drive the company's strategy. Meda is
represented by its own organizations in about 40 countries. Meda's products are
sold in 120 countries worldwide. The Meda share is listed under Large Cap on the
Nasdaq OMX Nordic Stock Exchange Stockholm. Find out more, visit www.meda.se.